HealthcareThe Global Price Anchor: Why 2026 is the Year of the "Glocal" Drug Strategy
Speyside Group analyzes the transformative "Great Healthcare Plan" of 2026, which has fundamentally redefined Pharmaceutical Market Access by linking U.S. drug pricing to international benchmarks. This shift toward a "glocal" strategy means that negotiation outcomes in Europe or APAC now act as a direct Global Price Anchor for the American market, effectively collapsing the divide between domestic and international pricing.
Read more